North America Cell Signaling Market

North America Cell Signaling Market Size (2023 to 2028)

The size of the North America Cell Signaling Market is forecasted to be growing at a CAGR of 6.1% between 2023 to 2028. This market was worth USD 1.37 billion in 2023 and estimated to worth USD 1.84 Billion by 2028 during the forecast period.

The growing incidence of chronic disease, the availability of funding for cellular research, technological improvements in cellular research instruments, and advancements in the biopharmaceutical and life sciences industries are the main drivers of the North American cell signaling market's growth. For example, according to the Centers for Disease Control and Prevention in 2012, approximately 134 million people in the United States had one or more chronic diseases. The development of microfluidics in cell biology research, the expansion of the geriatric population, the increasing applicability of cell signaling in biotechnology, and the improvement of the life science infrastructure are also facilitating cell growth signaling in North America.

The high cost of the system and the complexities associated with the development of reagents and antibodies are the significant challenges for the growth of the cell signaling market. Socio-ethical issues involved in stem cell research, such as religious relationships and the destruction of human embryos, are hindering factors.

This research report on the North America Cell Signaling Market has been segmented and sub-segmented into the following categories:

• By Type: Endocrine and Paracrine
• By Pathway: Akt, AMPK, Hedgehog, and Notch
• By Product: Consumables and Instruments
• By Technology: Flow Cytometry, ELISA and Mass Spectrometry
• By Application: Research, Cancer, and Immunology
• By Country: The United States, Canada, and Rest of North America

Regional Analysis:

North America holds a significant share of the cell signaling market and is expected to show a similar trend during the forecast period without substantial fluctuations. North America is the most considerable cell signaling market as the incidence of chronic disease increases in the region. For example, according to GLOBOCAN, around 1.8 million new cases of cancer were diagnosed in the United States, and there were 0.8 million cancer deaths in 2015. Besides, healthcare spending is increasing in America of the North, which has increased the accessibility and affordability of treatment for individuals. The expanding geriatric population, a large number of research institutes, and an improved life science infrastructure are also increasing the growth of the North American cell signaling market. In the United States, for fiscal 2019, the federal government has allocated $ 630 million, for the National Cancer Institute (NCI) budget, for breast cancer research, $ 224 million for colorectal cancer research, $ 274 million for leukemia. Besides, estimates available on the National Institute of Health's portal for stem cell research indicate a cumulative funding budget of over $ 3 billion for research in various areas of stem cell applications. The need for cell signaling in cancer research plays a vital role in the gradual growth of the cell signaling market in the United States. The increased funding for cancer research and stem cell research is directly driving an increase in cell signaling research, particularly in the United States. The growing trend of increasing research funding is expected to drive the growth of the studied market in the United States. 

Companies playing a dominant role in the North America Cell Signaling Market profiled in this report are Merck KGaA, Becton, Dickinson and Company, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Promega Corporation, Bio-Techne Corporation, Cell Signaling Technology, Inc., Abcam plc, Miltenyi Biotec, Cell Biolabs Inc., Full Moon BioSystems, Cisbio Bioassays, BioVision, Rockland Immunochemicals Inc., Tonbo Biosciences, StressMarq Biosciences Inc., BPS Bioscience, Abeomics Inc., RayBiotech, MEDICAL & BIOLOGICAL LABORATORIES CO, Sino Biological and Santa Cruz Biotechnology.